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Abstract
Coronavirus disease 2019 (COVID-19) and helminths infections can be in a synergistic epidemic in developing and
suburban areas of industrialized countries. The coinfected hosts will derive a parasite-specific Th2 innate and
adaptive immune response with CD4+ T cells, eosinophils, interleukin-4, interleukin-5, and interleukin-10. In the
early stages of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection, virus-specific Th1
cytotoxic CD8+ T cell, interleukin-6, interferon-γ, and interleukin-27 by lung are keys in controlling viral replication
in the lung epithelial cells and limiting the pathology to other organs, like the intestine. CD4+ and CD8+ T cells are
associated with protective immunity against and during COVID-19. However, viral evasion mechanisms occur.
Interference of the interferon-γ secretion, like in helminths immunomodulation, can contribute to COVID-19 severity.
Immunomodulation can result in mild, moderate, or severe COVID-19 depending on which helminth is coinfecting
by regulating or avoiding host cytokine and pro-inflammatory response, decreasing viral load, and affecting vaccineinduced antibody response. We discuss the implications of immunomodulation on COVID-19 caused by helminth
co-infection and for public health in the context of COVID-19 vaccine use in helminth endemic zones.
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Background
Intestinal parasite co-infections are current in
underdeveloped countries [1, 2] and areas of developed
countries [3]. Studies of intestinal parasites in
Venezuela for decades reveal high rates of infection.
These results demonstrated a high prevalence of
intestinal parasites (Entamoeba histolytica, Entamoeba
coli, Trichiura trichuris, and Ascaris lumbricoides), [4–
6], emerging pathogens, Cryptosporidium spp. [7] and
Cyclospora cayetanensis [8–10] and the most common
zoonotic human protozoa, Blastocystis spp. [11]. Soiltransmitted helminths (STH), Ascaris lumbricoides,
Toxocara spp., Taenia sp., and Strongyloides have been
reported in suburban areas of the US-Mexico
borderlands, inner cities, and the Appalachia area of the
United States of America [12].
Helminths have systemic immunomodulatory effects
triggered by their excretory/secretory helminth (E/S)
products [13, 14] and may influence the severity of
other infections. The host Th2 phenotype of the immune
response mediated by regulatory T cells [15] can
expulse the helminth parasite. However, established
helminths mostly have a well-tolerated chronic
infection by modulating the host immune response as a
parasite survival mechanism [16]. Diverse species of
helminths can infect humans. Human or zoonotic
helminth parasites can live in the intestine, in organs
such as the liver, lung, eye, and skin, in a specific
environment, or blood vessels. The host immune
response against the helminth will be different in each
one of these immunological microenvironments [14].
Extracellular (most intestinal helminths) and
intracellular pathogens (viral agents) will induce
different immune responses. Consequently, in cases of
co-infection, host responses against either of the
infecting pathogens can result in impaired or crossregulated. The immune regulation documented in coinfections can result in either an increase of pathology
[17] or protection [18] in the natural history of the
second infection.
Coronavirus disease 2019 (COVID-19) infections in
developing countries will be in a synergistic epidemic
with helminth neglected tropical diseases, called
syndemic [19]. The immune regulation of intestinal
helminth infection in humans coinfected by severe acute
respiratory syndrome coronavirus type 2 (SARS-CoV2), the pathological or protective consequences in the
natural history of the viral infection, and its possible
implications in vaccine efficacy in helminth endemic
zones is the focus of this review.

Helminth infections
Helminths are extracellular and multicellular organisms
that can parasite a host by crossing epithelial barriers.
2

Helminths can disrupt the epithelial layer and initiate
the cascade of inflammatory events [20].
Intestinal helminths can be transmitted orally by the
ingestion of eggs or by skin penetration of larvae. The
entry to the human body and the type of parasite
(zoonotic or not) contribute to defining the pattern of the
human immune response. The life cycle in the human
body is in organs (intestine, lungs, liver, skin, vessels)
and cellular tissues (endothelial, epithelial, and
neuronal).
Helminths' damage to tissues is followed by an
inflammatory microenvironment and a cascade of
events triggered by the helminth's E/S products [13, 21].
The most common E/S products in helminths are
enzymes (e.g. proteases, glycolytic enzymes), protease
inhibitors, venom allergen homologs, stress proteins,
and lectins [22–25]. Helminth E/S products are
responsible for the induction of Th2 immune
responsiveness [14, 26].
The first immune response to helminths is the innate
immunity type 2 response [26–28]. The leaders of this
response are the type Th2 innate lymphoid cells (ILC2s).
ILC2s, mast cells, basophils, γδ+ T cells, neutrophils,
and dendritic cells (DCs) are activated by the alarmin
type of cytokines released by epithelial cells [26, 28].
The recruitment of hematopoietic stem/progenitor cells
by alarmins, interleukin (IL)-25, IL-33 and thymic
stromal lymphopoietin to initiate a type 2 immune
response starts upon penetration of the parasite through
the epithelial barriers. The anti-helminth adaptive
immune response starts upon the release of type 2
cytokines (IL-4, IL-5, and IL-13) by ILC2s. Three
immune cells types will be the protagonist of this
response: lymphocyte type 2 cells (T helper Th2),
macrophage type 2, and immunoglobulin E (IgE)producing B cells [26].
The macrophage type 2 and eosinophils' activity can
eventually result in the expulsion of the parasites and
the healing of the affected epithelial tissues. Whenever
the parasite cannot be eliminated, the granuloma can
contain the infection. Type 2 immune response can
promote tolerogenic responses for adult schistosomes.
For instance, hepatic granuloma around the eggs will
permit the survival of Schistosoma in the host and
chronic disease status is maintained for several years
[29].

SARS-CoV-2 infection
Host cells penetration by SARS-CoV-2 occurs in
epithelial cells located in the oropharyngeal zone, lungs,
gut, and other body tissues using the surface
angiotensin-converting enzyme receptor 2 (ACE2) and
the transmembrane serine protease 2 [30]. Viruses,
having DNA or RNA genome structures to replicate, are
obligated intracellular organisms. The SARS-CoV-2
can attach to the cell through the binding domain of the
Submit a manuscript: https://www.tmrjournals.com/lr
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spike (S) protein by the human ACE2 receptor. The
SARS-CoV-2 will release its genomic material in the
cytoplasm and start to translate into proteins. The
subgenomic proteins, membrane (M) protein, spike (S)
glycoprotein, and envelope (E) protein will be
separately synthesized in the endoplasmic reticulum and
then moved to the endoplasmic reticulum-Golgi
intermediate compartment to join with the nucleocapsid
(N) protein. N protein will meet other proteins and form
vesicles that will be exported by exocytosis [30].
The N protein of SARS-CoV-2 is responsible for the
initial induction of the “cytokine storm” now called
early inflammatory phase [31] (IL-6, IL-10, IL-1β,
granulocyte-macrophage colony stimulatory factor,
tumor necrosis factor-alpha (TNF-α), interferon (INF)γ) [31, 32]. A hypothesis about the possible limitation
of COVID-19 severity has been discussed by others.
This hypothesis is about the idea of avoiding the
cytokine storm [18]. The multisystem inflammatory
syndrome can be seen in children infected with COVID19 (MIS-C) and for adults (MIS-A). It is part of the
multisystem inflammatory phase and is characterized by
peak levels of immunoglobulin G (IgG), secondary
infections, and many autoimmune events [31]. The
helminth tolerogenic response could modulate the
exaggerated immune responses by increasing IL-10
levels. The helminth E/S products can increment IL10 and are released during both phases, the early
inflammatory and the multisystem inflammatory [18].
Non-structural proteins (NSP) from SARS-CoV-2
are used by the virus in evasion mechanisms. NSP-1 can
suppress the work of INF through host translational
machinery inactivation [33]. NSP-16 suppresses the
work of INF through host translational machinery
inactivation and the global mRNA splicing in SARSCoV-1 infected cells, acting as a host virulence factor
[33]. And the global mRNA splicing in SARS-CoV-2
infected cells, acting as a host virulence factor [33].
SARS-CoV-2 by itself can also reduce CD3+, CD4+,
CD8+ T lymphocyte counts. Critical patients reflect the
severity of COVID-19 with low counts in CD8+ T
lymphocytes [34]. CD8+ T cells are important for viral
clearance by recognizing conservative regions on
viruses and elicit a protective response [34–36].
Older individuals, people with linked ACE2
expression or activity disorders (pre-diabetes, diabetes,
obesity, chronic hepatic disease, chronic pulmonary
disease, chronic intestinal disease, hypertension,
coagulopathies, renal disease, brain disease) [37–39], or
patients with immunocompromising conditions are at
higher risk of severe SARS-CoV-2 infection [40, 41].
The major concern is that ACE2 is expressed in 72
different cell types [42]. The expression of ACE2 can
be affected by factors such as sex, environment,
comorbidities, medications (e.g., anti-hypertensives),
interaction with genes of the renin-angiotensin system,
and other pathways. Those different factors can affect
Submit a manuscript: https://www.tmrjournals.com/lr

doi: 10.53388/life2021-0502-309

the risk of infection with SARS-CoV-2 and determine
the severity of the disease. The ACE2 enzyme is a
negative regulator of the renin-angiotensin system
(RAS) expressed in various organ systems, but ACE2 is
also related with innate immunity (complement),
inflammation, increased coagulopathy, cardiovascular
disease, metabolic disease, etc.; being involved in so
many fundamental functions, ACE2 is central in the
pathogenesis of COVID-19, and it is not a surprise to
find how COVID-19 can rapidly become a severe
disease [43–45]. Possibly, vaccination is more
challenging in populations having ACE2-related
disorders because the immunogenicity of vaccines is
diminished overall in these groups [46].

Innate immune response vs. COVID-19
The innate immune response will be responsible for the
early SARS-CoV-2 infection clearance in COVID-19.
The innate response will be crucial for the development
of clinical manifestations in the course and severity of
this disease. Innate immune cells contribute to resolving
the first stages of COVID-19 infection by using their Fc
receptor functions: complement-dependent cytotoxicity
(classic, lectin-mediated, alternative), antibodydependent cellular phagocytosis, or cellular-dependent
cytotoxicity [47].
Elimination of the virus can occur through
phagocytosis of virus-infected cells by alveolar
macrophages via Fc-receptor or the activation of
complement. Mannose-binding lectin (MBL), a pattern
of recognition molecule, can initiate the lectin pathway
of complement by binding to SARS-CoV-2. MBL is
considered to contribute to host defense against SARSCoV, although it might be associated with thrombosis
and coagulopathy in COVID-19 due to complement
pathway hyperactivation in critical patients [48]. MBL
deficiency is a susceptibility factor for the acquisition of
SARS-type virus [49].
The main viral antigen-presenting cells are DCs in the
lungs and will constitute a bridge to link innate with
adaptive immune response. Antigen-presenting cells are
crucial to initiating an adaptive immune response
directed by CD4+ T cell lymphocyte and cytotoxic T
cell CD8+ [50, 51].
The innate immune system type 1 can scan a variety
of pattern recognition receptors to find highly
conservative segments of SARS-CoV-2 [15]. Upon
recognition of the virus through pattern recognition
receptors by lung DCs and macrophages, INF-1 is
secreted [41, 52]. Some types of monocytes expressing
CD14 and CD62L can shift to secrete IFN and CCL2
chemokines (monocyte chemoattractant protein-1,
MCP-1) associated with a pro-fibrosis pattern seen in
severe lung COVID-19. Natural killer cells and alveolar
macrophages are the first-line defense of the innate
immune response against SARS-CoV-2 [15].
3
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The Th2 phenotype of an immune response drives
goblet cells hyperplasia and epithelial cells turnover
contributing to the integrity of the intestinal barrier
function and building up the mucus layers locally [30].
Investigations are needed to confirm if cell-mediated
Th2 and local goblet cells will contribute to the alveolar
barrier and the development of protection against
SARS-CoV-2.

Adaptive immune response vs. COVID-19
The CD4+ T cells are responsible for antibody
production and the CD8+ T cells for T cell antiviral
defense actions. SARS-CoV-2-specific CD4+ and
CD8+ T cells are associated with mild symptoms and
protective immunity during COVID-19 [51] due to
early viral clearance.
On the other hand, a rise in poor prognosis has been
associated with anti-viral CD8+ T cells [47]. Antibodies
interacting with the S protein can drive a neutralizing
viral activity [53]. The S protein or a portion of it [54]
have been used in models of the SARS-CoV-2 vaccines.
The receptor-binding domain of the S protein interacts
with the ACE2 receptor on human cells and permits cell
invasion. Pneumocytes and enterocytes are the major
target cells expressing ACE2 for SARS-CoV-2, playing
a central role in SARS-CoV-2 replication. Antibodies
induced by any anti-SARS-CoV-2 vaccine should give
rise to the production of neutralizing and protecting
anti-COVID-19 antibodies in the mucosal and other
tissues environments [55]. An adequate level of
neutralizing antibodies has been demonstrated in
symptomatic and convalescent individuals, but they did
not correlate with less severity of COVID-19 [56].
A less severe COVID-19 has been associated with
SARS-CoV-2-specific CD4+ and CD8+ T cells as part
of the adaptive cellular immune response [51]. Cellular
response induced by any anti-SARS-CoV-2 vaccine can
drive towards preventing severe illness [57], reducing
the number of hospitalizations and intensive care unit
(ICU) admissions [54] due to SARS-CoV-2, and
eventually reducing mortality due to complications for
COVID-19 [54, 57]. These features could be important
for helminth-coinfected COVID-19 individuals living
in endemic areas, also for 65 years and older [58], and
those with any co-morbidities severity of COVID-19
[51].

COVID-19 severe infections
COVID-19 severity is marked by a sudden health
deterioration caused by an excessive pro-inflammatory
immune response (cytokine storm) and/or an
endothelial (macro and micro thrombus) response that
leads to an acute respiratory distress syndrome (ARDS)
in the lungs and disseminated intravascular coagulation
in the whole organisms [59]. These two events are key
4
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to sudden COVID-19 increased severity [51, 59]. There
are three severe clinical phases for COVID-19: the early
inflammatory phase, the multisystem inflammatory
phase, and the tail phase [31].
It is well known that comorbidities (hypertension,
obesity, diabetes, cardiovascular disease, others) and
risk factors (smoking and vaping) can damage vascular
endothelial glycocalyx and contribute to COVID-19
severity
(ARDS,
disseminated
intravascular
coagulation, and Kawasaki disease shock syndrome).
COVID-19 severity in a population can be estimated by
measuring the raw fatality rate adjusting for
demography (e.g. stratified by age) under-ascertainment
[60]. The proportion of infected individuals hospitalized
for COVID-19 and the number of days required to be
discharged are other parameters used to estimate
COVID-19 severity [60].
COVID-19 patients admitted to the ICU exhibit a Th2
response pattern: IL-4, IL-5, IL-10, IL-13, and IL-25
[56]. Most of these patients had peripheral eosinophils
and basophils. Even though eosinophils can kill RNA
viruses using RNases inside their granules, the presence
of eosinophils and IL-6 has been reported as part of the
cytokine storm cascade and COVID-19 fatal cases [61].
Events occurring from day 0 to 4 of symptoms are
pivotal in the overall outcome of a COVID-19 patient.
The measure of a score ratio of IL-6/IL-10 in ICU
patients and obtaining the difference between day 0 to
4, predicted the outcome on day 7 [62]. This score is
named the Dublin-Boston [62] and permits to guide
clinical decision-making by identifying risk outcomes
in all types of COVID-19 hospitalized patients. The
Dublin-Boston score could be an indirect measure of the
double key role of IL-6 during the early stages of
COVID-19 and short-term outcomes [62].
A strong T cell CD8+ response that characterizes a
Th1 pattern is seen in individuals that clear viral
replication in 10 days or less. Th1 cells, induced by IL12 and producing IFN-γ, enhance the clearance of
intracellular pathogens, like viruses. A delay or
interference in the INF secretion (intracellular signals)
as seen for helminths infections that release substances
modulating early responding cells in innate immunity
(DCs and macrophages) [15] could permit invasion and
replication of the virus in the epithelial cells (lungs) and
invasion to other organs [15]. The use of a SARScoronavirus animal model with delayed INF-γ has been
used to describe a rapid virus replication and lung
pathology progress up to death [64].

Immunomodulation in helminth-COVID-19
co-infections
Intestinal helminths are a public health problem for
underdeveloped countries [5, 7, 65–67] and suburban
areas of developed countries. STH, Taenia spp.,
Echinococcus spp., and Schistosoma spp. are
Submit a manuscript: https://www.tmrjournals.com/lr
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helminth-SARS-CoV-2 co-infections under the innate
and adaptive response are illustrated in Table 1.

Table 1 Summarized immunomodulation of innate and adaptive immune response to SARS-CoV-2 in
helminth co-infections
Immune
response

Enhance viral protection

Increase viral pathology/severity in disease

Innate

1. Dependent PRR toll-like.

1. ↑ Alternative complement pathway by protein N
of SARS-CoV-2 → cytokine storm development ↑
IL-6, ↑ IL-1-β ↑ GMCSF, ↑ TNF-α.

2. CLR → ↓ viral.
3. NOD domain NOD→ ↓ viral.
4. Inflammasome → ↓ viral.

2. ↑ Chemokines, ↑ monocytes, ↑ neutrophils, and ↑
eosinophils.

5. RIG-I, MDA-5, CLR, NOD recognize highly 3. ↑ Mutations in spike (glycosylated region) →
conserved residues of SARS-CoV-2 → ↓ viral. difference in virulence, viral fusion, and mortality,
6. Vitamin D → ↑ Cathelicidin LL-37 and for instance, B1 clade (west coast of US) vs A2a
clade (east coast of US).
defensins.
7. AMP → ↓ viral.
Adaptive

1. Clonal expansion of CD8+ T cells in 1. ↑ Th2 immune response: T helper cells and Th2
individuals with mild to moderate symptoms cytokines: ↑ IL-4, ↑ IL-5, ↑ IL-9, and ↑ IL-13. ↑ Lung
can clear SARS-CoV-2 from the lungs.
macrophages. ↑ Pulmonary eosinophils. ↑ IL-10 →
2. A brief inflammatory phase → cleanup of ↓ Th1 response.
virus-infected cells by alveolar macrophages, 2. ↓ CD4+ T cells expressing INF-γ and TNF-α by
secretion of surfactant and IL-10, and TGF-β → Th2 cytokines.
anti-inflammatory lung microenvironment.
3. ↑ Defective INF-γ secretion by CD4+ T cells in
3. IL-4: ↑ T cell CD8+ (memory). ↑ T cell patients with COVID-19 severe symptoms.
CD8+ antigen-specific (antiviral, only in 4. Immune modulation towards Th2 → suppression
murine model).
of immune response against intracellular pathogens
(malaria, tuberculosis, and HIV/AIDS).
5. ↑ Eosinophils and ↑ IL-6 → cytokine storms →
fatal COVID-19 ↑ Th2 immune response in blood
smear of patients requiring intensive care for
COVID-19: ↑ eosinophils, ↑ basophils, ↑ immature
plasma cells, and ↓ T cell lymphocytes.

SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; PRR, pattern recognition receptors; NOD,
nucleotide-binding and oligomerization domain; CLR, C-type lectin receptors; RIG-I, retinoic acid inducible gene I,
functions as a cytosolic pattern recognition receptor; MDA-5, melanoma differentiation-associated gene 5 is a
cytosolic receptors for dsRNA; AMP, anti-microbial peptides; CD8+, subpopulation of MHC class I-restricted T cell
with CD8 co-receptor; IL, interleukin; TGF-β, transforming growth factor beta; GM-CSF, granulocyte-macrophage
colony stimulatory factor; TNF-α, tumor necrosis factor alpha; B.1, one of major lineage of SARS CoV-2 (B.1 clade)
and includes Alpha (B.1.1.7), Beta (B.1.315), Delta (B.1.617.2) and Gamma (B.1.1.28.1, an alias of P.1) variants;
A2a, is a lineage of SARS CoV-2 (A.2 clade) with a point mutation in the spike protein (D614G); Th1, T helper type
1 cells are a lineage of CD4+ effector T cell and secrete IFN-γ, IL-2, IL-10, and TNF-alpha/beta; CD4+ subpopulation
of MHC class II T-helper T cell with CD4+ receptor; Th2, T helper type 2 cells are CD4+ effector T cell and secretes
IL-4, IL-5, IL-9, IL-13, and IL-17E/IL-25; COVID-19, coronavirus disease 2019; HIV/AIDS human
immunodeficiency virus infection and acquired immune deficiency syndrome. Data extracted from the following
references [15, 17, 18, 35, 46, 47, 56, 87–89].
Helminths can suppress the inflammatory responses
survival inside this host could be enhanced or inhibited
occurring during infections by protozoa, bacteria, and
by this Th2 pattern [17, 47, 68]. A helminth/SARSviruses [58]. A human host infected with helminth
CoV-2 co-infection could lead to a defective T cell
before infection by SARS-CoV-2 is responding to the
response and low levels of IFN-I. Additionally,
helminth infection with a type 2 innate and adaptive
reprogramming macrophages from macrophage type 1
immune response [14]. SARS-CoV-2 replication and
to type 2, as a tolerance mechanism, has been previous
Submit a manuscript: https://www.tmrjournals.com/lr
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documented by other authors to be elicited by
Trichinella spiralis [69]. This supportive environment
for SARS-CoV-2 replication has been reported in
COVID-19 patients with a severe progression
characterized by lower levels of INF-γ and TNF-α in
CD4+ T cells [50].
Complexity in the overlapping events in the natural
history of the COVID-19 and participation of different
cofactors [70] can deliver a varicolored infection
outcomes and some some infected people have a fatal
end. Five COVID-19 phases (the viral symptom phase,
the early inflammatory phase, the secondary infection
phase, the multisystem inflammatory phase, and the tail
phase) have been described [31].
Helminth co-infections can compromise the host
immunological outcome and a spectrum response can
be seen during all five phases of COVID-19.
Immunomodulation created by a helminth-viral coinfection, specifically occurring for lung-cycle STH,
could permit a shorter pre-asymptomatic phase and
facilitate invasion, replication, and progression of the
viral infection [71]. The downregulation of the innate
and adaptive immune response takes an important role
in the co-evolution of both infections (Table 1). Evasion
mechanisms can be elicited simultaneously by the virus
and the helminth [58]. All types of coronavirus,
including SARS-CoV-1 and Middle East respiratory
syndrome coronavirus (MERS-CoV), use immune
evasion mechanisms to circumvent the innate and
adaptive immunity [50], in particular when escaping
detection of pattern recognition receptors by the host
innate immune response in early SARS-CoV-2
infection [50].
The initiation and maintenance of the symptomatic
COVID-19 period would be characterized by high
levels of neutralizing antibodies in the acute and
convalescence period. The presence of neutralizing
antibodies was not associated with less disease severity
[51].
From the point of view of the adaptive immune
response, SARS-CoV-2 can make use of antibodydependent enhancement (ADE) mechanisms to evade
the immune system. The virus may use ADE and
macrophages Fc receptor to enter and re-program host
cells for proinflammatory cytokines production-like IL6, that would support virus replication and survival [59].
Anti-inflammatory cytokines type 2-like IL-10 are
frequently present in helminth-infected humans [71]
and could play an important role in stopping the
cytokine tissue damage in the early and multisystem
inflammatory phases. IL-6 promotes the production of
IL-27 by lung macrophages in a host infected by the
respiratory syncytial virus [52]; at the same time, IL-27
promotes the local maturation of regulatory T cells. IL6 could have a double key role as a proinflammatory
cytokine and as a local regulation of lung Th1 response.
Similarly, IL-6 in SARS-Cov-2 infection could limit
6

REVIEW
infection and viral lung immunopathology by inducing
the production of IL-27. A study demonstrates high
levels of IL-6 and a decreased levels of IL-27 in
psoriasis patients at risk for COVID-19. None of the
patients developed severe symptoms or complications
post-COVID-19. IL-27 levels did not lead to an
increased risk for SARS-CoV-2 infection [72].
Another cytokine with a dual role is IL-33. IL-33 is
secreted by the lung DCs. The helminth mouse model
of Nippostrongylus brasiliensis demonstrated that IL-33
can promote type 2 inflammation in epithelial cells by
stimulating ILC-2 but also can drive immunoregulation
through expansion of Treg by DCs. It is not clear if the
downregulation of innate and cellular adaptive immune
response against SARS-CoV-2 driven by lung DCs can
play an anti-inflammatory role in the natural history of
COVID-19. Tuft cells -present in the intestine and
lungs- can produce IL-25 and IL-33 in response to
helminth and elicit the production of ILC2s, which
produce IL-4 and IL-13 [14].

COVID-19 infections in helminth endemic
areas
The immune system will respond in a different way to
helminths and viruses after overpassing the host
epithelial barriers. In general, helminths establish longlived, chronic infections characterized by broad downmodulation of both the innate and adaptive arms of host
immunity [20].
The burden and impact data for COVID-19 for each
country is still not accurate because this pandemic is an
ongoing situation. America, followed by Europe and
South-East Asia has been the most affected regions in
the world for COVID-19.
STH burden and impact data can vary from one
country to another. And in the same country, we can
find areas of high or low transmission of helminths.
Each country has a different reality for helminth
prevalence and species, in some cases, there is a marked
difference between regions in the same country, for
instance, Brazil.
From an epidemiological and public health point of
view, the helminth species present in each endemic area
will influence the outcome of a helminth-COVID-19
co-infection. As stated above, a helminth infection can
determine protection or severity against a COVID-19 in
individuals and populations co-infected with helminths,
specifically with STH. To address the status of
protection or severity in a co-infected region will permit
to plan public health measures adaptable to that region,
for instance, deworming, type of COVID-19 vaccine to
be used, and other preventable measures.
If the development of protection against SARS-CoV2 infection is feasible in cases of chronic helminth
infections in immunomodulated hosts, global
helminthiasis endemic areas should have less severe and
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fatal COVID-19 cases. This hypothesis has been
documented in Sub-Saharan Africa with high STH
prevalence where co-infection promotes a low lethality
for COVID-19 [58, 73]. On the other hand, India, an
Asiatic country with a wide range of endemic helminth
areas is occupying 2nd place worldwide, after the
United States of America, with 30,082,778 confirmed
cases of COVID-19 and 390,660 deaths, reported to
WHO [74].
The STH prevalence in India varies from high to low
depending on the helminth species (high for Ascaris
lumbricoides, low for Trichuris trichiura, and
intermediate and low for hookworm). The most
common STH is A. lumbricoides. STH prevalence is
high in some regions (Bahir, Tamil Nadu, and Jammu
and Kashmir); it is intermediate in Maharashtra and low
in Delhi’s [75]. The immunomodulation outcome for
helminth-COVID-19 co-infections in those regions
shows the evident difference among regions in which
regions with high STH prevalence, mainly by A.
lumbricoides (Bahir), COVID-19 severity appeared to
be prevented, whereas in the Delhi region with lower
STH prevalence more severe cases for COVID-19 were
occurring (Figure 1). Regions with high to intermediate
prevalence for STH are more probable to develop mild
to moderate cases of COVID-19. The data for India
(Figure 1) was extracted from the total death table of the
center for system science and engineering at John
Hopkins University [76] of the tracking coronavirus in
India: Latest Map and Case Count document [77]. The
COVID-19 severity in India has not been estimated by
measuring the raw fatality rate nor adjusting for by age,
so we have plotted COVID-19 severity (reported as a
share in population deaths) vs. classes of severity
intensities for STH [75].
In Latin America, Brazil is 3rd placed worldwide and
st
1 place in this region for COVID-19 infections
(18,054,653) and deaths (504,717) [74]. Like India,
Brazil is also an endemic country for STH in South
America, Ascaris lumbricoides and hookworm having
intermediate (20%–50%) to the high percentage (50%–
100%) of prevalence. However, the percentages of
prevalence in Brazil appear lower than those seen in
India. By contrast, the rates of lethality for COVID-19
are higher than those seen in India for some states.
Minas Gerais, a very low-income state, has a high
prevalence of A. lumbricoides and intermediate
prevalence of hookworm [78]. The data about the share
in population deaths for COVID-19 severity in Brazil’s
states was not accessible. Nonetheless, the lethality rate
for Minas Gerais appears inexplicably very high (25.49)
compared to Rio de Janeiro state (5.81); Rio de Janeiro
has a low prevalence for all STH [78].
If the hypothesis about a protective status from
SARS-CoV-2 during co-infection with helminths and
diminished immunopathology is viable, three new
questions should arise to understand viral clearance and
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resolution for COVID-19:
 Which immunomodulation would be more
important - inhibition of Th1 or increase of Th2
immune response?
 Which would be the best timeline in the natural
history of the disease to stop immune pathology?
 Would this status be helpful for a host with
comorbidities, like diabetes and obesity?
Further investigation should be done to demonstrate
if this can be an in vivo possibility for the helminthSARS-CoV-2 model [18].
The diversity of helminth/other pathogens coinfection results in human hosts are such that is not easy
to make general conclusions from these results. Table 2
summarizes how some co-infections can compromise
the host immunological pathogenesis outcome or
contribute to resolving, for instance, a viral infection.
Animal models and experimental STH infections
have limitations in generating the natural immunity and
long-live lasting history of most STH infections in
endemic areas as occurring in nature. Nonetheless,
helminths can often affect the evolution of co-infection
by making animals more resistant to other pathogens in
which protection is mediated by the Th2-like response
and more susceptible to other pathogens in which
protection is mediated by the Th1-like response [18, 26].
Other pathogens can also influence the immune
response against helminths, depending on which
infection was installed first [26].

COVID-19 vaccinations in helminth endemic
areas
A COVID-19 vaccine should impel an innate immune
response in the respiratory system followed by an
adaptive response to impede SARS-CoV-2 infection.
To trigger mucosal immunity the inoculation of the
vaccine should be via a respiratory mucosal route [28].
This route is not feasible for all vaccine models. A
CD4+
T
cell
Th2
respiratory
mucosal
microenvironment is present in individuals infected by
helminths because most geohelminths have larvae stage
life cycle migrating through the lungs [79, 80]. An
individual infected by helminth has a different
respiratory mucosal microenvironment before the
COVID-19 vaccine is administered. It is not clear if the
anti-inflammatory immune status present in a helminth
infection will diminish in COVID-19 vaccinated hosts
and if the post-vaccine immune system can prevent a
cytokine storm outcome.
Helminths may influence vaccine efficacy by
modulating the host immune response when Th1-like
and cellular-dependent responses are required for the
2nd -arrived pathogen, as would be the case for a
helminth-COVID-19 co-infection (Table 3). The
immunomodulatory effects of helminth infections can
mitigate vaccination efficacy [46, 79]. Chronic
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helminthiasis has a more negative impact on
immunization than acute disease [80]. Furthermore,
individuals could be polyparasitized and it will be
necessary to evaluate the overall effect resulting from
immunomodulation for more than one parasite.
An excellent example is the use of the Litomosoides
sigmodontis infected mice model to demonstrate how
helminth infection reduces the quantity and quality of
antibody responses to vaccination against seasonal
influenza (Table 2) [52, 55]. In helminth-infected mice,
IL-10 was responsible for this viral immunosuppression,
which was partially repealed by the in vivo blockade of
the IL-10 receptor by a neutralizing anti-IL-10 receptor
monoclonal antibody after Influenza vaccination,
restoring immunoglobulins response. The sustained
expansion for over 90 days of IL-10 producing-CD4+-

type 1 regulatory T cells inhibited the production of
viral-specific antibodies (IgG1, IgG2b, and IgG2c) [81].
Helminth co-infection impact over viral vaccination
can be diminished by using either antiparasitic
medication before vaccination or several boosts to
induce a T cell help response and neutralizing
antibodies as part of the adaptive immune response. The
first alternative is more feasible. Deworming can
decrease SARS-CoV-2 viral load and improve T cell
CD8+ in the lung microenvironment. Mass deworming,
as recommended by WHO for endemic areas [82]
before the implementation of the COVID-19 vaccine
will be a pharmacological intervention that could
improve anti-SARS-CoV-2 protection in helminth
infected individuals and future trials could elucidate

Figure 1 STH/COVID-19 co-infections and immunomodulation outcome in India. This is a partial representation
of COVID-19 severity (in terms of deaths) in four helminth-endemic Indian regions with different STH prevalence
percentages (%) [75]. Bahir region: high STH prevalence and at least 1 in 10,886 residents died; possible protective
immunomodulation and less severe cases for COVID-19. Jammu and Kashmir region (high to intermediate STH
prevalence), and Maharashtra region (intermediate to low STH prevalence) with 1 in 2,874 and 1 in 976 fatalities,
respectively; moderate to severe cases for COVID-19. Delhi region: with low STH prevalence and more severe cases
for COVID-19 (1 in 673 deaths). Since the beginning of the pandemic, at least 1 in 3,486 residents have died from
COVID-19 in India. And a total of 391,981 deaths up to June 23, 2021 [74, 76, 77]. STH, soil-transmitted helminth;
COVID-19 coronavirus disease 2019.
Table 2 Co-infections compromise the host immunological pathogenesis outcome and infections
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Host

Species

Parasite

Virus

Effect

Reported mechanisms

Human

T. spiralis

Nematode

Influenza A

↑ Helminth-induced
immune-response ↓
Virus-induced

↓ inflammatory
infiltration in the lungs; ↓
production in
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pathological
changes.

bronchoalveolar lavage
fluid.

Mice

Fasciola hepatica

Trematode

SARSCoV-2

Modulation of hyper
inflammation
reactions in the
lungs by suppressing
the proinflammatory
component.

Helminths inhibit SARSCoV-2 entry into host
cells → induces antiinflammatory effects → ↓
COVID-19 pathology.

Human

Schistosoma
mansoni

Trematode

HIV

↑ Transmission of
HIV.

↓ CD4 T cells.
Deworming → decreases
HIV viral load and ↑
CD4+ counts among
HIV-infected individuals.

NonHuman
primate
model

Schistosoma
mansoni

Trematode

HPV

Helminth-induced
immune response ↑
HPV disease
progression.

Chronic S. mansoni
infection ↓ protective
HPV-specific IgG
antibodies induced by
vaccination. Treatment of
schistosomiasis with PZQ
before HPV vaccination
→ reversed this effect
supporting antihelminthic treatment
before vaccination.

Mice

Heligmosomoides.
polygyrus

Nematode

RSV

Helminth-induced
immune response ↓
RSV pulmonary
disease.

↑ Type I interferon
signaling protects against
the pulmonary virus
infection through
interaction with the
microbiota.

Mice

Litomosoides
sigmondontis

Filarial
nematode

FV

Helminth infection
interfered with the
control of the
retroviral infection.

Increased viral loads in
co-infected mice were
associated with ↓ titers of
neutralizing FV-specific
IgG2b and IgG2c
antibodies.

Birds &
Mammals

Echinoparyphium
sp. (amphibian
parasite)

Trematode

Amphibian
ranavirus

Helminth infection ↓
virus load.

Helminth infection ↓
ranavirus replication
possibly through crossreactive immunity.

SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; HIV, human immunodeficiency virus; HPV,
human papillomavirus; RSV, respiratory syncytial virus; FV, friend virus retrovirus. Data extracted from the
following references, T. spiralis [90]; F. hepatica [68]; S. mansoni [19, 91]; H. polygyrus [92]; L. sigmondontis [93];
Echinoparyphium sp. [94].

Table 3 Course of COVID-19, previous helminth co-infection and after COVID-19 vaccination
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Immune
response

SARS-CoV-2 infection

SARS-CoV-2 and previous
chronic helminth infection

Previous chronic helminth
infection and anti- SARS-CoV2 vaccine

Innate

Rapid reduction of viral load
by PRR and innate immune
cells.

Impair reduction of viral load
by the effect of parasite
immune evasion mechanisms.

If vaccine ↑ T cell response,
anti-helminth response impairs
this response, COVID-19
manifest. If the vaccine ↑
neutralizes and or protects
antibodies, COVID-19 may not
manifest.

Adaptive

IL-6/IL-10 is positive. Viral
infection resolution by Th1
type immune response in
lungs: macrophages and
CD8+ T cells clone
expansion.

IL-6/IL-10 is negative.
Immune response in lungs
inhibits Th1 response.
↑Pulmonary eosinophils. Low
INF-γ and TNF-α.

IL-6/IL-10 may be negative or
positive. Helminth co-infection
immune-suppression can alter
COVID-19 vaccine cellular and
humoral response (↑, ↓ or no
modification).

Infection
Outcome

Th2-type anti-inflammatory
lung microenvironment by
IL-10, surfactant, and TGFβ.

↑ Excretory/Secretory
helminth products: ↑ Th2-type
anti-inflammatory lung
microenvironment products by
IL-10 and IL-33, can avoid
cytokine storm and/or impair
viral resolution.

Mild symptoms and Th2-type
anti-inflammatory can avoid
cytokine storm.
Moderate symptoms and antiCOVID-19 vaccine antibodies
would ↓ viral load and possibly
disease progression.
Severe symptoms and
suppression of vaccine-induced
immunity efficacy and cytokine
storm effects.

COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; PRR,
pattern recognition receptors; IL, interleukin; CD8+, subpopulation of MHC class I-restricted T cell with CD8 coreceptor; Th2, T helper type 2 cells are CD4+ effector T cell and secrete IL-4, IL-5, IL-9, IL-13, and IL-17E/IL-25;
TGF-β, transforming growth factor beta; IFN-γ, interferon gamma; TNF-α, tumor necrosis factor alpha.
COVID-19 vaccination impact [81, 83]. Schistosoma
infections are associated with increase transmission of
HIV and deworming decreased HIV viral load and
improved CD4+ counts among HIV-infected
individuals [19].
A placebo-controlled doubleblind trial conducted in
Central Africa (Gabon) demonstrated the effect over the
immune response after a single dose of albendazole
(400 mg) before influenza immunization. Children in
the treated group had higher levels of total antibodies,
even though specific immunoglobulin A titles were not
significantly different. Higher titers of immunoglobulin
A, IgG1, and IgG3 against both influenza A strains and
memory B-cell response were modestly higher in the
treated group [83]. Antibody levels can be different and
influenced by the burden and type of prevalent parasite
in the endemic population. The use of alternative
treatment schedules- single vs two or more doses before
vaccination is another variable to consider in future
trials.
10

Not always anti-helminthic treatment can modify the
immune response unbalance. After 16 years of
ivermectin treatment, a negative Th1/Th2 response
persisted in Oncocerca volvulus’s infected population
characterized by high levels of IL-10, IgG1, and IgG4
[84].
Some developing countries include the use of the
Bacillus Calmette-Guérin (BCG) vaccine in their
national control program. It has been hypothesized that
BCG vaccination can epigenetically modulate the innate
immune response leading to an enhanced cytokine
response by TNF-α, IL-1β, and IL-6. BCG has been
demonstrated to reduce viral titers (Influenza, vaccinia,
and Herpes virus) in infected mice by
immunomodulation [85].
Other alternative strategies to counterbalance the
immunomodulatory effects of helminths in coinfections have been proposed before proceeding to
anti-COVID-19 vaccinations in the helminth endemic
areas, such as the use of a specific adjuvant [[26], use of
Submit a manuscript: https://www.tmrjournals.com/lr
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a human monoclonal antibody to block SARS-CoV-2
infection, immune-modulating therapies, and massive
deworming of endemic communities [15].

Conclusions and future perspectives
Preliminary studies of helminth endemic communities
before COVID-19 vaccination should include
community information about the implementation of
preventive measures. Helminth co-infections may
downregulate the efficient immune response against
SARS-CoV-2 in the early stage of the infection, thereby
increasing morbidity and mortality in COVID-19
patients. Helminth infections can suppress the immune
responses and can mitigate SARS-CoV-2 vaccine
efficacy [79].
To know the status of protection or severity in a coinfected region will permit to plan public health
measures adaptable to a specific area, for instance,
deworming, type of COVID-19 vaccine to be used, and
other preventable measures.
We propose the previous evaluation of the IL-6/IL10 score in helminth endemic communities, to predict
vaccine response in helminth neglected tropical disease
areas. It may be useful to map around the world whether
helminth-infected communities will be susceptible to
COVID-19 infection or able to inhibit it after
vaccination against COVID-19.
The outcome, equilibrium, and timeline of each
proinflammatory/anti-inflammatory cytokine (IL-6/ IL10 ratio) can elucidate how helminth previous infection
can influence the natural history of COVID-19 disease
and immune response after COVID-19 vaccination.
A re-installation of an anti-inflammatory lung
microenvironment is crucial for less severe disease, as
confirmed by some studies [86]. Th2 pattern cytokines,
like IL-10, can inhibit the inflammatory cascade of
cytokines in those individuals simultaneously
coinfected by helminths and SARS-CoV-2:
 Individuals with mild symptoms can have a brief
inflammatory phase followed by a cleanup of
virus-infected cells by alveolar macrophages,
secretion of surfactant and IL-10, and transforming
growth factor-beta (TGF-β).
 Th2 pattern cytokines predominate in long-term
helminth infected individuals and helminth
endemic communities. This pattern is also
dependable on helminth species and host-parasite
burden.
 The production of IL-6 followed by IL-27 permits
the recruitment and well-functioning of a cellular
adaptive response commanded by regulatory T
cells as key for stopping SARS-CoV-2 replication
and limiting the infection period reaching a full
convalescence in COVID-19.
We have hypothesized here that the innate and the
adaptive host immune response against the COVID-19
Submit a manuscript: https://www.tmrjournals.com/lr
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vaccine can be different (enhancing, deteriorating, or no
modification) in helminth-infected vs. non-helminthinfected hosts. Examples discussed in this work suggest
that the hypothesis may have relevant epidemiological
and anti-COVID-19 vaccination implications in STH
endemic areas coinfected with the SARS-CoV-2 virus.
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